DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20175684

Effect of agomelatine on psychomotor function tests in healthy human volunteers

G. Sirisha, Shovan P.

Abstract


Background: Agomelatine is a melatonergic agonist that acts specifically on MT1/MT2 melatonergic receptors and 5-HT2C antagonism. The present study was taken up to evaluate the effect of Agomelatine 25mg on psychomotor function in healthy human volunteers.

Methods: The effect of Agomelatine was studied in 12 healthy volunteers of either gender. The study was a randomised, cross over, placebo controlled study, done after obtaining permission from NIMS Institutional Ethics Committee and informed consent taken from all the subjects, after briefly explaining the study procedure and training them adequately. Psychomotor function was assessed using Choice reaction time (CRT), Critical Flicker fusion test (CFFT), Digit letter substitution test (DLST), Six letter cancellation test (SLCT), Card sorting test (CST) and Visual analog scale (VAS). Psychomotor function tests were performed, 90 minutes after administering Agomelatine 25 mg or placebo. Washout period of seven days was allowed between the cross over. Statistical analysis was done by comparing groups using unpaired t test.

Results: There was significant decrease in the mean percentage of time (p<0.01) in CRT in Agomelatine group (20.09±9.47%) when compared to placebo (10.48±3.68%). Improved mean percentage of performance was seen in CFFT with Agomelatine (6.2±2.1%) compared to placebo (9.11±2.99%). No significant difference was noted in the performance of DLST, SLCT and CST. Drug was subjectively rated as sedative on VAS.

Conclusions: There is no significant effect of Agomelatine on psychomotor performance. CNS processing of information also improved. Agomelatine can thus be safely administered to depressed patients.


Keywords


Agomelatine, Information processing, Psychomotor performance, sedative, Visual analog scale

Full Text:

PDF

References


Katzung BG. Basic & Clinical Pharmacology 11ed.New York: Lange Medical Publications; 2009:509.

Srinivasan VR, Zakaria R, Othman Z, Edward CL, Dario AC. Agomelatine in depressive disorders: its novel mechanisms of action. The J of Neuropsychiatry and Clinical Sciences. 2012;24(3):290-308.

Kennedy HS, Cyriac A. A dimensional approach to measuring antidepressant response: implications for Agomelatine. Psychology. 2013;3(10):864-9.

Girish MB, Bhuvana K, Nagesh Raju G, Sarala N. A novel atypical antidepressant drug: A review. Int J Pharm Biomed Res. 2010;1(3):113-6.

Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmac. 1980;10:189-209.

Kasper S, Hajak G, Wulff K, Hoogendijk WJG, Montejo AL, Smeraldi E, et al. Efficacy of Novel antidepressant Agomelatine on circadian rest activity cycle and depressive and anxiety symptoms in patients with Major Depressive Disorder: A randomized, double blind comparison with Sertraline. J Clin Psychiatry. 2010;71(2):109-20.

Stone BM. Pencil and paper tests: sensitivity to psychotropic drugs. Br J Clin Pharmac. 1984;18:155-205.

Turner P. Critical flicker frequency and centrally acting drugs. Br J Ophthal. 1968;52:245-50.

Balaram P. Effect of kapalbhati on performance of six letter cancellation test and digit letter substitution task in adults. Int J Yoga. 2013 Jul-Dec;6(2):128-30.

Aitken RCB. Measurement of feelings using visual analogue scales. Proc Roy Soc Med. 1969;62:989-93.

Nelson JC, Charney DS. The symptoms of major depressive illness. The American J of Psychiatry. 1998;138(1):1-13.

Roger ML, Hanlon FJ. Cognitive and Psychomotor Effects of Antidepressants with Emphasis on Selective Serotonin Reuptake Inhibitors and the Depressed Elderly Patient. German J Psychiatry. 1999;2(1):51-80.

Mets AJ, Deventer KR, Olivier B, Verster JC. Next-Day Effects of Ramelteon (8mg), Zopiclone (7.5mg), and Placebo on Highway Driving Performance, Memory Functioning, Psychomotor Performance, and Mood in Healthy Adult Subjects.

Michele F, Davide P, Salvatore C, Giulio P. A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation. Current Neuropharmacology. 2010;8:287-304.

Srinivasan V, Pandi-Perumal SR, Trakht I, Spence DW, Hardeland R, Poeggeler B. Pathophysiology of depression: role of sleep and the melatonergic system Psychiatry Res. 2009 Feb 28;165(3):201-14.

Mets AJ, Deventer KR, Olivier B, Verster JC. Critical appraisal of ramelteon in the treatment of insomnia. Nat Sci Sleep. 2010;2:257-66.

Gary Z, Milton E. Evaluation of the Efficacy and Safety of Ramelteon in Subjects with Chronic Insomnia. J Clin Sleep Med. 2007 Aug 15;3(5):495-504.

Bertaina-Anglade V, Drieu-La-Rochelle C, Mocaër E, Seguin L. Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacol. Biochem. Behav. 2011;98:511-7.

Sarfaraz AK, Mukesh CM, Anand K, Avinash T. Acute Effects of Citalopram and Imipramine on Psychomotor Performance in Healthy Volunteers: A Comparative Study. J Pharm Sci & Res. 2011;3(6):1269-75.

Jhanjee A, Bhatia MS, Shruthi S, Kumar P. Agomelatine: A new antidepressant with a novel mechanism of action. Delhi Psychiatry J. April 2010;13(1):170-8.